DK2041129T3 - Inhibitorer af human proteintyrosinphosphatase og deres farmaceutiske anvendelse - Google Patents

Inhibitorer af human proteintyrosinphosphatase og deres farmaceutiske anvendelse

Info

Publication number
DK2041129T3
DK2041129T3 DK07809909.0T DK07809909T DK2041129T3 DK 2041129 T3 DK2041129 T3 DK 2041129T3 DK 07809909 T DK07809909 T DK 07809909T DK 2041129 T3 DK2041129 T3 DK 2041129T3
Authority
DK
Denmark
Prior art keywords
inhibitors
protein tyrosine
human protein
pharmaceutical use
tyrosine phosphatase
Prior art date
Application number
DK07809909.0T
Other languages
English (en)
Inventor
Mathew Brian Maier
Jeffrey Lyle Gray
Cynthia Monesa Clark
Kande Amarasinghe
Ryan Nichols
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38704718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2041129(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Application granted granted Critical
Publication of DK2041129T3 publication Critical patent/DK2041129T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07809909.0T 2006-06-27 2007-06-27 Inhibitorer af human proteintyrosinphosphatase og deres farmaceutiske anvendelse DK2041129T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81682506P 2006-06-27 2006-06-27
PCT/US2007/014824 WO2008002571A2 (en) 2006-06-27 2007-06-27 Human protein tyrosine phosphatase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
DK2041129T3 true DK2041129T3 (da) 2014-10-13

Family

ID=38704718

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14166121.5T DK2803663T3 (da) 2006-06-27 2007-06-27 Human protein tyrosin-phosphatase-inhibitorer og deres farmaceutiske anvendelse
DK07809909.0T DK2041129T3 (da) 2006-06-27 2007-06-27 Inhibitorer af human proteintyrosinphosphatase og deres farmaceutiske anvendelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14166121.5T DK2803663T3 (da) 2006-06-27 2007-06-27 Human protein tyrosin-phosphatase-inhibitorer og deres farmaceutiske anvendelse

Country Status (23)

Country Link
US (3) US7589212B2 (da)
EP (3) EP3287455A1 (da)
JP (1) JP5201740B2 (da)
KR (1) KR101157844B1 (da)
CN (1) CN101506204B (da)
AU (1) AU2007265455B2 (da)
BR (1) BRPI0713349A2 (da)
CA (1) CA2656915C (da)
CO (1) CO6150143A2 (da)
CY (1) CY1115588T1 (da)
DK (2) DK2803663T3 (da)
ES (2) ES2510674T3 (da)
HK (2) HK1129388A1 (da)
IL (1) IL196130A (da)
MX (1) MX2009000290A (da)
NZ (1) NZ574405A (da)
PL (2) PL2803663T3 (da)
PT (2) PT2041129E (da)
RU (1) RU2430101C2 (da)
SI (1) SI2041129T1 (da)
TR (1) TR201802280T4 (da)
WO (1) WO2008002571A2 (da)
ZA (1) ZA200900558B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
AU2014202211B2 (en) * 2009-01-12 2016-06-02 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
EP2385763B1 (en) * 2009-01-12 2018-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2496084B1 (en) 2009-11-06 2015-06-10 Aerpio Therapeutics Inc. Compositions and methods for treating colitis
JP2013539756A (ja) * 2010-10-07 2013-10-28 アエルピオ セラピューティックス インコーポレイテッド 眼球浮腫、血管新生および関連疾患を処置するための組成物および方法
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
RU2507597C2 (ru) * 2012-05-23 2014-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ фармакологической коррекции ишемии скелетной мышцы никорандилом
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CA2903871A1 (en) 2013-03-15 2014-09-18 Aerpio Therapeutics Inc. Formulations with increased solubility of compounds that activate tie-2
RU2526466C1 (ru) * 2013-04-04 2014-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Средство для стимуляции васкуляризации сердечной мышцы при постинфарктном ее ремоделировании в эксперименте
SG11201606862VA (en) 2014-02-19 2016-09-29 Aerpio Therapeutics Inc Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
JP6483148B2 (ja) * 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
CA3030298A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.)
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
US10900319B2 (en) 2017-12-14 2021-01-26 Exacta-Frac Energy Services, Inc. Cased bore straddle packer
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
CA3156225A1 (en) 2019-10-29 2021-05-06 EyePoint Pharmaceuticals, Inc. Small molecule activators of tie-2
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673641A (en) * 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1225226B1 (en) * 1992-03-13 2007-12-05 bioMerieux B.V. Peptides and nucleic acid sequences related to Epstein Barr Virus
EP0642353A1 (en) * 1992-05-14 1995-03-15 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5688781A (en) 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
DK0833934T4 (da) * 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
JPH106346A (ja) * 1996-06-19 1998-01-13 Takemoto Oil & Fat Co Ltd プラスチック成形型の製造方法及びプラスチック成形型
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
AU5062500A (en) 1999-04-26 2000-11-10 Amersham Pharmacia Biotech Ab Primers for identifying typing or classifying nucleic acids
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
WO2000070030A1 (en) * 1999-05-19 2000-11-23 Amgen Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
CA2382789A1 (en) 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US6589758B1 (en) * 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
CN1571796A (zh) 2000-09-27 2005-01-26 宝洁公司 黑皮素受体配体
AU2003222127A1 (en) * 2002-03-29 2003-10-13 Ontogen Corporation Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US20050154011A1 (en) * 2003-02-20 2005-07-14 The Procter & Gamble Company Tetrahydroisoquinolnyl sulfamic acids
US20040242676A1 (en) * 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
WO2005027183A2 (en) * 2003-09-17 2005-03-24 Koninklijke Philips Electronics N.V. High intensity discharge lamp
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells

Also Published As

Publication number Publication date
DK2803663T3 (da) 2018-03-05
ZA200900558B (en) 2012-04-24
JP5201740B2 (ja) 2013-06-05
KR101157844B1 (ko) 2012-06-22
US7589212B2 (en) 2009-09-15
ES2510674T3 (es) 2014-10-21
EP2803663B1 (en) 2017-11-29
JP2009542660A (ja) 2009-12-03
WO2008002571B1 (en) 2008-04-17
ES2660571T3 (es) 2018-03-23
EP3287455A1 (en) 2018-02-28
CA2656915C (en) 2012-08-07
PL2041129T3 (pl) 2014-11-28
US20120077853A1 (en) 2012-03-29
MX2009000290A (es) 2009-03-16
AU2007265455A2 (en) 2009-05-21
CA2656915A1 (en) 2008-01-03
CN101506204B (zh) 2012-05-30
PT2041129E (pt) 2014-10-08
RU2430101C2 (ru) 2011-09-27
IL196130A (en) 2014-04-30
CY1115588T1 (el) 2017-01-04
TR201802280T4 (tr) 2018-03-21
EP2041129B1 (en) 2014-09-03
HK1203960A1 (en) 2015-11-06
PT2803663T (pt) 2018-02-28
BRPI0713349A2 (pt) 2012-03-06
PL2803663T3 (pl) 2018-05-30
HK1129388A1 (en) 2009-11-27
CN101506204A (zh) 2009-08-12
WO2008002571A3 (en) 2008-02-14
US20090227639A1 (en) 2009-09-10
SI2041129T1 (sl) 2014-11-28
IL196130A0 (en) 2009-09-22
US8188125B2 (en) 2012-05-29
NZ574405A (en) 2012-01-12
WO2008002571A2 (en) 2008-01-03
CO6150143A2 (es) 2010-04-20
EP2041129A2 (en) 2009-04-01
RU2009102537A (ru) 2010-08-10
EP2803663A1 (en) 2014-11-19
AU2007265455A1 (en) 2008-01-03
KR20090024296A (ko) 2009-03-06
AU2007265455B2 (en) 2011-11-10
US20070299116A1 (en) 2007-12-27
US8338615B2 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
DK2041129T3 (da) Inhibitorer af human proteintyrosinphosphatase og deres farmaceutiske anvendelse
DK3323815T3 (en) Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
IL196129A0 (en) Human protein tyrosine phosphatase inhibitors and methods of use
LTPA2017004I1 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK2089361T5 (da) Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse
DK2019825T3 (da) Inhibitorer af human immundefektvirus-replikation
BRPI0717317A2 (pt) Modularoes da proteína cinase triazalopiridazina
CY2014011I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK3279663T3 (da) Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme
DK1924577T3 (da) Substituerede benzimidazoler og fremgangsmåder til fremstilling
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
EP1812012A4 (en) PROTEIN TYROSINE PHOSPHATASE INHIBITOR AND METHOD FOR THEIR USE
DK2297106T3 (da) Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
BRPI0907236A2 (pt) inibidores de proteína quinase e uso dos mesmos
DK2043671T3 (da) Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber
DK1833495T3 (da) Dermatologisk anvendelse af mælkeproteiner
BRPI0906867A2 (pt) inibidores terapêuticos da função pai-1 e métodos de uso dos mesmo
DK1803732T3 (da) Peptider og derivater af APL-TYPE af HSP60 og famaceutiske sammensætninger
DK2094699T3 (da) Hidtil ukendte imidazolonderivater, fremstilling deraf som lægemidler, farmaceutiske præparater og anvendelse deraf som hæmmere af proteinkinaser, især cdc7
DK2032593T3 (da) Aminoderivater af B-homoandrostaner og B-heteroandrostaner
DK2046118T3 (da) Herbicidal sammensætning og fremgangsmåde til anvendelse heraf
DK2106401T3 (da) Derivater af pyrrolopyridin-2-carboxamider, fremstilling deraf og terapeutisk anvendelse deraf
ZA200900492B (en) Human protein tyrosine phosphatase inhibitors and methods of use